Efficacy of PTX3 and posaconazole combination in a rat model of invasive pulmonary aspergillosis.

Abstract

Posaconazole is currently used for the prophylaxis of invasive pulmonary aspergillosis (IPA). Limitations to posaconazole usage are drug-drug interactions and side effects. PTX3 is an innate immunity glycoprotein with opsonic activity, proven to be protective in IPA animal models. This study investigated the combination of posaconazole with PTX3. The results indicate synergy between PTX3 and posaconazole against aspergillosis, suggesting that a combination of reduced doses of posaconazole with the immune response enhancer PTX3 might represent a treatment option with a higher therapeutic index than posaconazole.

• Authors: Emanuele Marra, Vitor L Sousa, Roberta Gaziano, M Lucrezia Pacello, Brunilde Arseni, Luigi Aurisicchio, Rita De Santis, Giovanni Salvatori
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 58 Issue 10 Pg. 6284-6 (Oct 2014) ISSN: 1098-6596 [Electronic] United States
• PMID: 25070103 (Publication Type: Journal Article)
• Copyright: Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Chemical References

• Antifungal Agents
• Serum Amyloid P-Component
• Triazoles
• PTX3 protein
• posaconazole
• C-Reactive Protein

Topics

• Animals
• Antifungal Agents (pharmacology)
• C-Reactive Protein (pharmacology)
• Drug Synergism
• Invasive Pulmonary Aspergillosis (drug therapy)
• Male
• Rats
• Serum Amyloid P-Component (pharmacology)
• Triazoles (pharmacology)